BioCentury | Jan 18, 2016
Clinical News

Archexin: Interim Phase IIa data

...2-stage, open-label Phase IIa trial showed that once-daily 125, 200 and 250 mg/m 2 IV Archexin...
...in their tumor size of 16% and 36% following 4 and 2 treatment cycles, respectively. Archexin...
...Afinitor alone in 30 RCC patients. Rexahn Pharmaceuticals Inc. (NYSE-M:RNN), Rockville, Md. Product: Archexin ( RX-0201...
BioCentury | Oct 1, 2015
Product R&D

Escaping the liver

...co-lipids and pegylated lipids Unspecified Unspecified Liver; Tumors Cancer Phase Ib/IIa Rexahn Pharmaceuticals Inc. (NYSE-M:RNN) RX-0201-nano...
BioCentury | Jul 24, 2014
Cover Story

It is an RNA world

...Ltd. MTL-501 Preclinical Rexahn Pharmaceuticals Inc. (NYSE-M:RNN) RX-0201-nano...
...Cancer Renal cell carcinoma Rexahn Pharmaceuticals Inc. Archexin...
BioCentury | Jan 27, 2014
Clinical News

Archexin: Phase IIa started

...Rexahn began a 2-stage Phase IIa trial of Archexin plus Afinitor everolimus. A dose-escalation portion in...
...with metastatic RCC will determine the maximum tolerated dose (MTD). The second stage will compare Archexin...
...NYSE:NVS; SIX:NOVN, Basel, Switzerland) markets Afinitor. Rexahn Pharmaceuticals Inc. (NYSE-M:RNN), Rockville, Md. Product: Archexin ( RX-0201...
BioCentury | Jan 20, 2014
Finance

Highlights of weekly biotech stock moves

...Phase IIa trial of Archexin ( RX-0201 ) to treat metastatic renal cell carcinoma (RCC). Archexin...
BioCentury | Jan 16, 2014
Financial News

Rexahn planning $20 million direct offering

...Wainwright are placement agents. On Tuesday, Rexahn started a Phase IIa trial of Archexin ( RX-0201...
BioCentury | Oct 21, 2013
Company News

Rexahn, The Ohio State University deal

...compounds into tumors, which can result in improved safety and efficacy. Rexahn plans to develop RX-0201-nano...
BioCentury | Sep 3, 2012
Clinical News

Archexin: Phase IIa data

...Indian Phase IIa trial in 31 patients aged 18-65 with metastatic pancreatic cancer showed that Archexin...
...adverse events were constipation, nausea, abdominal pain and pyrexia. Patients received 250 mg/m 2/day IV Archexin...
...RCC), glioblastoma, stomach and ovarian cancer. Rexahn Pharmaceuticals Inc. (NYSE-M:RNN), Rockville, Md. Product: Archexin ( RX-0201...
BioCentury | Sep 3, 2012
Finance

Highlights of weekly biotech stock moves

...from a single-arm, open-label Phase IIa trial in patients with metastatic pancreatic cancer showed that Archexin...
BioCentury | Aug 28, 2012
Clinical News

Rexahn reports top-line data for Archexin in pancreatic cancer

...a single-arm, open-label Phase IIa trial in 31 patients with metastatic pancreatic cancer showing that Archexin...
...company plans to start a Phase IIa trial of the compound to treat ovarian cancer. Archexin...
Items per page:
1 - 10 of 20